| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifitegrast | SHP-606; SAR-1119; SAR-1118; SPD-606; OJL-332 | Approved | Shire Development Llc | Xiidra, 朗悦明 | United States | Dry Eye Syndromes | Bausch And Lomb Inc | 2016-07-11 | Conjunctivitis, Allergic; Diabetic macular oedema; Dry Eye Syndromes; Graft vs Host Disease; Keratoconjunctivitis Sicca; Xerophthalmia | Details |